Skip to main content
Erschienen in: Diabetologia 6/2005

01.06.2005 | Article

RETRACTED ARTICLE: Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats

verfasst von: Y. Hattori, K. Akimoto, S. S. Gross, S. Hattori, K. Kasai

Erschienen in: Diabetologia | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Hypertension, endothelial dysfunction and insulin resistance are associated conditions that share oxidative stress and vascular inflammation as common features. Adiponectin is an abundant plasma adipokine that plays a physiological role in modulating lipid metabolism and exerts a potent anti-inflammatory activity. We hypothesised that adiponectin levels decrease in response to oxidative stress and that this may promote the development of hypertension, endothelial dysfunction and insulin resistance.

Methods

Rats were infused with angiotensin II (AngII) or its vehicle, either alone or in combination with tempo1 (4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl), a membrane-permeable metal-independent superoxide dismutase mimetic, or tetrahydrobiopterin (BH4), one of the most potent naturally occurring reducing agents and an essential cofactor for nitric oxide synthase activity. Heart rate, systolic blood pressure, body weight and serum levels of adiponectin were measured on day 7 of treatment, and then the animals were killed. Vessel tone and superoxide production were measured ex vivo in thoracic vascular rings. The expression of adiponectin mRNA in adipose tissue was assessed by Northern blotting, and in 3T3-L1 adipocytes exposed to H2O2 by real-time PCR. The expression of NAD(P)H oxidase subunit mRNAs in the rats was assessed by RT-PCR and real-time PCR.

Results

Hypertension and endothelial dysfunction were induced in rats by infusion of AngII and reversed by administration of tempol. Plasma concentrations of adiponectin and adipose tissue levels of adiponectin mRNA were decreased in AngII-infused rats, and this effect was prevented by cotreatment with tempol or BH4. The production of superoxide anions (O2 ) was significantly increased in the aortae of AngII-treated rats, and this increase was prevented by the administration of tempol or BH4. Levels of mRNAs that encode NAD(P)H oxidase components, including p22phox, gp91phox, p47phox and Rac1, were similarly increased in adipose tissue, aortae and hearts of AngII-infused rats. Cotreatment of rats with tempol or BH4 reversed AngII-induced increases in NAD(P)H oxidase subunit mRNAs. Fully differentiated 3T3-L1 adipocytes, also exhibited diminished adiponectin mRNA levels when exposed to low concentrations of H2O2.

Conclusions/interpretation

Our results demonstrate that AngII-induced oxidative stress and endothelial dysfunction are accompanied by a decrease in adiponectin gene expression. Since antioxidants were observed to prevent the actions of AngII, and H2O2 on its own suppressed adiponectin expression, we conclude that adiponectin gene expression is negatively modulated by oxidative stress. Plasma adiponectin levels may provide a useful indicator of oxidative stress in vivo, and suppressed levels may contribute to the proinflammatory and metabolic derangements associated with type 2 diabetes, coronary artery disease and the metabolic syndrome.
Literatur
1.
Zurück zum Zitat Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRef Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRef
2.
Zurück zum Zitat Ouchi N, Kihara S, Arita Y et al (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476PubMed Ouchi N, Kihara S, Arita Y et al (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476PubMed
3.
Zurück zum Zitat Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMed Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMed
4.
Zurück zum Zitat Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89PubMedCrossRef Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89PubMedCrossRef
5.
Zurück zum Zitat Ouchi N, Kihara S, Arita Y et al (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102:1296–1301PubMed Ouchi N, Kihara S, Arita Y et al (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102:1296–1301PubMed
6.
Zurück zum Zitat Ouchi N, Kihara S, Arita Y et al (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063PubMed Ouchi N, Kihara S, Arita Y et al (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063PubMed
7.
Zurück zum Zitat Arita Y, Kihara S, Ouchi N et al (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893–2898PubMedCrossRef Arita Y, Kihara S, Ouchi N et al (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893–2898PubMedCrossRef
8.
Zurück zum Zitat Matsuda M, Shimomura I, Sata M et al (2002) Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem 277:37487–37491PubMedCrossRef Matsuda M, Shimomura I, Sata M et al (2002) Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem 277:37487–37491PubMedCrossRef
9.
Zurück zum Zitat Okamoto Y, Kihara S, Ouchi N et al (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767–2770PubMedCrossRef Okamoto Y, Kihara S, Ouchi N et al (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767–2770PubMedCrossRef
10.
Zurück zum Zitat Kubota N, Terauchi Y, Yamauchi T et al (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–26866PubMedCrossRef Kubota N, Terauchi Y, Yamauchi T et al (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–26866PubMedCrossRef
11.
Zurück zum Zitat Suwaidi JA, Hamasaki S, Higano ST et al (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948–954PubMed Suwaidi JA, Hamasaki S, Higano ST et al (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948–954PubMed
12.
Zurück zum Zitat Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899–1906PubMed Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899–1906PubMed
13.
Zurück zum Zitat Hattori Y, Suzuki M, Hattori S, Kasai K (2003) Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia. 46:1543–1549PubMedCrossRef Hattori Y, Suzuki M, Hattori S, Kasai K (2003) Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia. 46:1543–1549PubMedCrossRef
14.
Zurück zum Zitat Shimabukuro M, Higa N, Asahi T et al (2003) Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88:3236–3240PubMedCrossRef Shimabukuro M, Higa N, Asahi T et al (2003) Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88:3236–3240PubMedCrossRef
15.
Zurück zum Zitat Tan KC, Xu A, Chow WS et al (2004) Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 89:765–769PubMedCrossRef Tan KC, Xu A, Chow WS et al (2004) Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 89:765–769PubMedCrossRef
16.
Zurück zum Zitat Laursen JB, Rajagopalan S, Galis Z (1997) Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95:588–593PubMed Laursen JB, Rajagopalan S, Galis Z (1997) Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95:588–593PubMed
17.
18.
Zurück zum Zitat Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494–501PubMed Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494–501PubMed
19.
Zurück zum Zitat Ogihara T, Asano T, Ando K et al (2002) Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40:872–879PubMedCrossRef Ogihara T, Asano T, Ando K et al (2002) Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40:872–879PubMedCrossRef
20.
Zurück zum Zitat Hansson L, Lindholm LH, Niskanen L et al (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 353:611–616PubMedCrossRef Hansson L, Lindholm LH, Niskanen L et al (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 353:611–616PubMedCrossRef
21.
Zurück zum Zitat Yusuf S, Gerstein H, Hoogwerf B et al (2001) Ramipril and the development of diabetes. JAMA 286:1882–1885PubMedCrossRef Yusuf S, Gerstein H, Hoogwerf B et al (2001) Ramipril and the development of diabetes. JAMA 286:1882–1885PubMedCrossRef
22.
Zurück zum Zitat Dahlof B, Devereux RB, Kjeldsen SE (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003PubMedCrossRef Dahlof B, Devereux RB, Kjeldsen SE (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003PubMedCrossRef
23.
Zurück zum Zitat Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin-type 1 receptors. Diabetes 51:1699–1707PubMedCrossRef Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin-type 1 receptors. Diabetes 51:1699–1707PubMedCrossRef
24.
Zurück zum Zitat Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM (2002) Hormonal regulation of the human adipose-tissue renin–angiotensin system: relationship to obesity and hypertension. J Hypertens 20:965–973PubMedCrossRef Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM (2002) Hormonal regulation of the human adipose-tissue renin–angiotensin system: relationship to obesity and hypertension. J Hypertens 20:965–973PubMedCrossRef
25.
Zurück zum Zitat Schnackenberg CG, Wilcox CS (1999) Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin F2alpha. Hypertension 33:424–428PubMed Schnackenberg CG, Wilcox CS (1999) Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin F2alpha. Hypertension 33:424–428PubMed
26.
Zurück zum Zitat Schnackenberg CG, Wilcox CS (2001) The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes. Kidney Int 59:1859–1864PubMedCrossRef Schnackenberg CG, Wilcox CS (2001) The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes. Kidney Int 59:1859–1864PubMedCrossRef
27.
Zurück zum Zitat Hong HJ, Hsiao G, Cheng TH, Yen MH (2001) Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 38:1044–1048PubMedCrossRef Hong HJ, Hsiao G, Cheng TH, Yen MH (2001) Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 38:1044–1048PubMedCrossRef
28.
Zurück zum Zitat Vasquez-Vivar J, Kalyanaraman B, Martasek P et al (1998) Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 95:9220–9225PubMedCrossRef Vasquez-Vivar J, Kalyanaraman B, Martasek P et al (1998) Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 95:9220–9225PubMedCrossRef
29.
Zurück zum Zitat Higashi M, Shimokawa H, Hattori T et al (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93:767–775PubMedCrossRef Higashi M, Shimokawa H, Hattori T et al (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93:767–775PubMedCrossRef
30.
Zurück zum Zitat Mukai Y, Shimokawa H, Higashi M et al (2002) Inhibition of renin–angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol 22:1445–1450PubMedCrossRef Mukai Y, Shimokawa H, Higashi M et al (2002) Inhibition of renin–angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol 22:1445–1450PubMedCrossRef
31.
Zurück zum Zitat Kashiwagi A, Shinozaki K, Nishio Y et al (1999) Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 277:E976–E983PubMed Kashiwagi A, Shinozaki K, Nishio Y et al (1999) Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 277:E976–E983PubMed
32.
Zurück zum Zitat Hattori Y, Kasai K, Gross SS (2004) NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Cardiovasc Res 63:31–40PubMedCrossRef Hattori Y, Kasai K, Gross SS (2004) NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Cardiovasc Res 63:31–40PubMedCrossRef
33.
Zurück zum Zitat Hattori Y, Gross SS (1993) GTP cyclohydrolase I mRNA is induced by LPS in vascular smooth muscle: characterization, sequence and relationship to nitric oxide synthase. Biochem Biophys Res Commun 195:435–441PubMedCrossRef Hattori Y, Gross SS (1993) GTP cyclohydrolase I mRNA is induced by LPS in vascular smooth muscle: characterization, sequence and relationship to nitric oxide synthase. Biochem Biophys Res Commun 195:435–441PubMedCrossRef
34.
Zurück zum Zitat Lassegue B, Sorescu D, Szocs K et al (2001) Novel gp91phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88:888–894PubMedCrossRef Lassegue B, Sorescu D, Szocs K et al (2001) Novel gp91phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88:888–894PubMedCrossRef
35.
Zurück zum Zitat Tirosh A, Potashnik R, Bashan N, Rudich A (1999) Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 274:10595–10602PubMedCrossRef Tirosh A, Potashnik R, Bashan N, Rudich A (1999) Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 274:10595–10602PubMedCrossRef
36.
Zurück zum Zitat Shimokawa H (1999) Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 31:23–37PubMedCrossRef Shimokawa H (1999) Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 31:23–37PubMedCrossRef
37.
Zurück zum Zitat Rajagopalan S, Kurz S, Munzel T et al (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 97:1916–1923PubMedCrossRef Rajagopalan S, Kurz S, Munzel T et al (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 97:1916–1923PubMedCrossRef
38.
Zurück zum Zitat Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141–1148PubMed Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141–1148PubMed
39.
Zurück zum Zitat Pagano PJ, Clark JK, Cifuentes-Pagano ME (1997) Localization of constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci U S A 94:14483–14488PubMedCrossRef Pagano PJ, Clark JK, Cifuentes-Pagano ME (1997) Localization of constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci U S A 94:14483–14488PubMedCrossRef
40.
Zurück zum Zitat Fukui R, Ishizaka N, Rajagopalan S et al (1997) p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80:45–51PubMed Fukui R, Ishizaka N, Rajagopalan S et al (1997) p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80:45–51PubMed
41.
Zurück zum Zitat Furuhashi M, Ura N, Higashiura K et al (2003) Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76–81PubMedCrossRef Furuhashi M, Ura N, Higashiura K et al (2003) Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76–81PubMedCrossRef
42.
Zurück zum Zitat Agata J, Nagahara D, Kinoshita S et al (2004) Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J 68:1194–1198PubMedCrossRef Agata J, Nagahara D, Kinoshita S et al (2004) Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J 68:1194–1198PubMedCrossRef
43.
Zurück zum Zitat Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084–1089PubMedCrossRef Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084–1089PubMedCrossRef
Metadaten
Titel
RETRACTED ARTICLE: Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats
verfasst von
Y. Hattori
K. Akimoto
S. S. Gross
S. Hattori
K. Kasai
Publikationsdatum
01.06.2005
Erschienen in
Diabetologia / Ausgabe 6/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1766-7

Weitere Artikel der Ausgabe 6/2005

Diabetologia 6/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.